Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ajinomoto's Earthquake Response At Fukushima: A Business Continuity Case Study

This article was originally published in PharmAsia News

Executive Summary

Shinji Oshiguchi, the plant manager for Ajinomoto's Fukushima production plant, outlines the precautionary steps, response, and restarting protocols during a natural disaster.

You may also be interested in...

Business Continuity Vital In Japan For Companies Like Daiichi Sankyo On Slow Road To Recovery; Earthquake Impacts Organizational Moves

TOKYO - An emerging view of the damage to pharmaceutical companies in Japan points to a scenario in which affected companies must find a way to ensure business continuity while simultaneously beginning a slow recovery

Southwest Japan-heavy Takeda And Dainippon Sumitomo Spared Earthquake Damage, Others May Rebound, But Tokyo Headquarters' Quieted By Rail Disruptions

TOKYO - Offices across Tokyo remained closed Tuesday, stalling the operations of headquarters for many pharma and medical device companies in Japan as the city faced train and highway closures and threats of blackouts through the rest of the week. Meanwhile, stocks for many of the Japanese pharma tumbled on the Nikkei March 14 in response to the emergency at power plants in Fukushima prefecture

FCPA In The China Framework Warrants Special Attention

The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts